Less Is More: Patients With Colon Cancer Get a Chemo Break Less Is More: Patients With Colon Cancer Get a Chemo Break
Data show that 3 months of oxaliplatin-based chemotherapy is as effective as 6 months but has less toxicity, good news for patients with colon cancer.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 4, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Will Adjuvant Oxaliplatin Data Change Practice in CRC? Will Adjuvant Oxaliplatin Data Change Practice in CRC?
Dr John Marshall previews the GI cancer studies being presented at ASCO with his picks for the ones to watch, and predicts that a plenary presentation may be practice-changing.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 26, 2017 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news
Adjuvant GEMOX Did Not Improve RFS for Localized Biliary Tract Cancer
Adjuvant chemotherapy for biliary tract cancer using GEMOX (gemcitabine/oxaliplatin) was feasible, but did not result in an improved recurrence-free survival or quality of life compared with surveillance in the phase III PRODIGE 12-ACCORD 18 trial. (Source: CancerNetwork)
Source: CancerNetwork - January 23, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Conferences/ASCO 2017 Gastrointestinal Cancers Symposium Liver, Gallbladder, and Biliary Tract Cancers News Source Type: news
Middle-Aged Man With Acute Thrombocytopenia Subsequent to Fluorouracil and Oxaliplatin Chemotherapy for Colorectal Cancer
A 44-year-old patient with a history of stage IIB colorectal cancer at the hepatic flexure, invading the duodenum and pancreas, was initially diagnosed in September 2005 and received modified Whipple surgery and 8 cycles of adjuvant chemotherapy with capecitabine and oxaliplatin every 3 weeks. (Source: CancerNetwork)
Source: CancerNetwork - November 15, 2016 Category: Cancer & Oncology Authors: Henning Schade, MD Lindsey Davis, MD Peter Kabos, MD Tags: Case Studies Colorectal Cancer Oncology Journal Source Type: news
High-capacity nanoparticle holds potential for targeted cancer therapies
Image: Jeremiah Johnson
Chemists from the Mass. Institute of Technology developed a nanoparticle that they can pack with 3 or more drugs to create custom combination therapies for cancer, according to a study published this week in the Journal of the American Chemical Society.
The team also revealed that cisplatin, a powerful anti-cancer drug, doesn’t work using the same DNA-damaging mechanism when delivered via nanoparticle compared to traditional methods.
The team uses a unique nanoparticle production method, which they 1st reported in 2014. Instead of trying to load the drugs onto nanoparticles that are already built,...
Source: Mass Device - September 15, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Drug-Device Combinations Oncology Research & Development Mass. Institute of Technology Source Type: news
Colon Cancer With Microsatellite Instability: Adjuvant Chemo Colon Cancer With Microsatellite Instability: Adjuvant Chemo
Is deficient mismatch repair colon cancer resistant to adjuvant 5-fluorouracil plus oxaliplatin?Journal of the National Cancer Institute (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 24, 2016 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Molecule prevents effect of chemotherapy
(Aarhus University Hospital) For the last three years the research team has been working on the development of a so-called biomarker to predict treatment effectiveness. Now the researchers found a molecule which is closely associated with the effect of Oxaliplatin treatment, an anti-cancer drug widely used in the treatment of colorectal cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 16, 2016 Category: Cancer & Oncology Source Type: news
Rectal Cancer: Oxaliplatin-based Preoperative Chemoradiation Rectal Cancer: Oxaliplatin-based Preoperative Chemoradiation
Does preoperative 5 x 5 Gy irradiation and FOLFOX4 consolidation chemotherapy improve outcomes in rectal cancer? < br / > < i > Annals of Oncology < /i > (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 29, 2016 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Oxaliplatin-Based Adjuvant Chemo for Stage III MMR CRC Oxaliplatin-Based Adjuvant Chemo for Stage III MMR CRC
Oxaliplatin-based adjuvant chemotherapy was be better than surgery alone for patients with stage 3 colorectal cancer with mutations in DNA mismatch repair genes. < br / > < i > Medscape Medical News < /i > (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 22, 2016 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Oxaliplatin Can Be Safely Infused at a Rate of 1 mg/m2/minOxaliplatin Can Be Safely Infused at a Rate of 1 mg/m2/min
A study finds that oxaliplatin can be infused safely at a faster rate than previously determined and hopefully this will result in less overall treatment time and improved patient satisfaction. Journal of Oncology Practice (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 9, 2016 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Researchers Identify Best Drug Therapy for Rare, Aggressive, Pancreatic Cancer
JACKSONVILLE, Fla. — Each year, about 200 to 400 Americans develop pancreatic acinar cell carcinoma, a rare form of pancreatic cancer that has no effective standard of care. A study involving researchers on Mayo Clinic’s Florida and Rochester campuses has found that the chemotherapy drug oxaliplatin is effective in stopping the growth of this cancer. [...] (Source: Mayo Clinic Research News)
Source: Mayo Clinic Research News - May 25, 2016 Category: Research Source Type: news
Debiopharm International SA Has Won Its Patent Infringement Suit for Elplat(R) Against Nippon Kayaku Co., Ltd.
LAUSANNE, Switzerland, March 4, 2016 -- (Healthcare Sales & Marketing Network) -- Debiopharm International SA (Debiopharm), part of Debiopharm Group, a Swiss-based global biopharmaceutical company today announces that the Tokyo District Court granted Deb... Biopharmaceuticals, Generics, Oncology, LitigationDebiopharm Group, Elplat, Oxaliplatin, Nippon Kayaku Co (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 4, 2016 Category: Pharmaceuticals Source Type: news
New method of drug delivery may be safer and more effective against pancreatic cancer
The overall five-year survival rate for people with pancreatic cancer is just 6 percent, and there is an urgent need for new treatment options. More than 80 percent of pancreatic cancer diagnoses occur too late for surgery, making chemotherapy the only possible treatment.
Scientists from the California NanoSystems Institute at UCLA and UCLA’s Jonsson Comprehensive Cancer Center have developed a delivery system for one chemotherapy drug that greatly reduces the occurrence of serious side effects while enhancing the drug’s effectiveness against pancreatic cancer. The approach uses mesoporous silica nanoparticles to deliv...
Source: UCLA Newsroom: Health Sciences - March 2, 2016 Category: Universities & Medical Training Source Type: news
Success of Platinum Desensitization 'Depends on the Agent'Success of Platinum Desensitization 'Depends on the Agent'
Cancer patients receiving oxaliplatin are more likely to experience hypersensitivity reactions during desensitization than those given carboplatin. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 2, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Evaluation of NK1 antagonists for emesis prevention in oxaliplatin chemo: SENRI trial
The SENRI trial has opened the window to evaluate NK1 antagonists for emesis prevention in patients taking oxaliplatin chemotherapy, results of a new study. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - July 1, 2015 Category: Science Source Type: news
